PathoVax
Share
PathoVax LLC is developing breakthrough vaccines against infectious diseases and cancers utilizing a Human Papillomavirus Virus-Like Particle (HPV VLP) platform that has been exclusively licensed from the Johns Hopkins University. This technology is generated by the same investigators responsible for existing HPV vaccines, and can be used to present other antigens to induce robust humoral or cellu
05/14/2019
PathoVax LLC is pleased to have a presence back in Boston as part of the family at . We are also very pleased to be alongside fellow Singaporean Company 🇸🇬🇺🇸
01/02/2018
Proud feature in the Baltimore Business Journal. We hope to bring this positive momentum into 2018!
updated with article link! http://bizj.us/1phbiq
Hopkins-born startup PathoVax wins $2.5 million, nears clinical trial readiness - Baltimore Business Journal The grants came through the National Institute of Allergy and Infectious Diseases and the National Science Foundation.
Click here to claim your Sponsored Listing.
Category
Website
Address
Baltimore, MD
